Document Detail

Advanced prostate cancer-a case for adjuvant differentiation therapy.
MedLine Citation:
PMID:  22890299     Owner:  NLM     Status:  Publisher    
The development of novel therapies such as abiraterone acetate and sipuleucel-T has improved the outlook for patients with advanced-stage and castration-resistant prostate cancer. However, the beneficial effects of these drugs are only measured in months. Moreover, the National Institute for Health and Clinical Excellence in the UK had ruled that the use of abiraterone acetate was not cost-effective before cost revision by the manufacturers. The FDA statement asserting that the use of 5α-reductase inhibitors for prostate cancer chemoprevention could increase the risk of developing high-grade prostate cancer also indirectly questions the value of direct androgen response manipulation for long-term benefit. These reports illustrate the need for a fresh and comprehensive analysis of advanced prostate cancer pathology to promote the next generation of effective adjuvant therapies. One such avenue is that of differentiation therapy, which seeks to promote the differentiation of cancer stem cells into a phenotype more sensitive to anticancer therapy than their parents. Using differentiation therapy with current antiandrogen therapies should augment our armoury of treatment for the management of advanced prostate cancer.
Jayant K Rane; Davide Pellacani; Norman J Maitland
Related Documents :
22672199 - High-intensity focused ultrasound (hifu) for definitive treatment of prostate cancer.
24175199 - Antineoplastic effects of mammalian target of rapamycine inhibitors.
24656869 - Periostin: a novel prognostic and therapeutic target for genitourinary cancer?
22790989 - The new era of staging as a key for an appropriate treatment for esophageal cancer.
23707669 - Long term consumption of flaxseed enriched diet decreased ovarian cancer incidence and ...
136929 - Types of mesenchymal reactions in the carcinoma of uterine cervix.
12397729 - Emergency surgery for patients with colorectal cancer over 90 years of age.
21771059 - Prebiotics: germinated barley foodstuff for the prevention of colitis-associated colon ...
22444719 - Experience of young women diagnosed with breast cancer who undergo fertility preservati...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-14
Journal Detail:
Title:  Nature reviews. Urology     Volume:  -     ISSN:  1759-4820     ISO Abbreviation:  Nat Rev Urol     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101500082     Medline TA:  Nat Rev Urol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Yorkshire Cancer Research Unit, Department of Biology (Area 13), University of York, York YO10 5DD, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of Laryngeal Findings on Acoustic Parameters of Patients with Laryngopharyngeal Reflux.
Next Document:  Normal and neoplastic urothelial stem cells: getting to the root of the problem.